Flowvium
Kembali ke Explorer

Eli Lilly and Company

LLYleader

Eli Lilly is the world's most valuable pharmaceutical company, propelled by the blockbuster GLP-1 receptor agonist tirzepatide (Mounjaro/Zepbound) for diabetes and obesity. Its Alzheimer's antibody donanemab and strong oncology pipeline give it one of the most promising drug portfolios in the industry.

Bagikan:
⇄ Compare

Produk & Pendapatan

Pangsa Pendapatan Produk

Komposisi Pendapatan ($52.8B)

Data statis (memuat keuangan langsung…)

Diabetes & Obesity (52%)
Oncology (18%)
Immunology (12%)
Neuroscience (10%)
Other (Insulin Legacy) (8%)

Komposisi segmen dan pelanggan utama

Detail produk

Mounjaro / Zepbound (tirzepatide)38%

GLP-1/GIP dual agonist for type 2 diabetes and obesity

Verzenio (abemaciclib)14%

CDK4/6 inhibitor for breast cancer

Taltz / Olumiant10%

Immunology — psoriasis and atopic dermatitis treatments

Donanemab (Kisunla)8%

Anti-amyloid antibody for early Alzheimer's disease

Insulin Portfolio (Humalog, Basaglar)12%

Insulin products with declining but significant revenue

Hubungan Rantai Pasok

Pesaing

Novo Nordisk

GLP-1 / obesity drugs

Dampak: Primary competitor — GLP-1 duopoly

Pfizer Inc.

Large-cap pharma pipeline

Dampak: Competing in oncology and metabolic

Regeneron Pharmaceuticals

Antibody therapeutics

Dampak: Competing in biologics

Mitra

Moderna, Inc.

Potential oncology collaboration

Dampak: Exploratory

Konteks makro dan pasar

제약 / 바이오Berita sektor

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Katalis mendatang

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Masalah rantai pasokan

★ 기회Orforglipron 3상 긍정 예비 결과
2026-04

경구 GLP-1 Orforglipron 3상 체중감소 -15.6% 확인. 주사 Wegovy와 동등 수준. 2027 허가 목표로 NDA 준비.

↑ 생산 확대인디애나 제조시설 $9B 투자 확정
2026-03

GLP-1 원료의약품(API) 수급 안정을 위해 미국 내 자체 생산 투자. CDMO 의존도 50%→30% 목표.

Sinyal Institusional

InstitusiTindakanNilaiKuartalTanggal pengajuan
BlackRockaccumulating$1.8B2024.062024-08-13↑
BlackRockaccumulating$672M2024.062024-08-13↑
BlackRockaccumulating$676M2024.062024-08-13↑
BlackRockaccumulating$56M2024.062024-08-13↑
BlackRockaccumulating$105M2024.062024-08-13↑
BlackRockaccumulating$2.2B2024.062024-08-13↑
BlackRockaccumulating$2.1B2024.062024-08-13↑
BlackRockaccumulating$21.8B2024.062024-08-13↑
BlackRockaccumulating$16.4B2024.062024-08-13↑
BlackRockaccumulating$1.3B2024.062024-08-13↑
BlackRockaccumulating$1.8B2024.062024-08-13↑
BlackRockaccumulating$830M2024.062024-08-13↑
BlackRockaccumulating$1.7B2024.062024-08-13↑
BlackRockreducing$18M2024.062024-08-13↓
BlackRockaccumulating$5.2B2024.062024-08-13↑
BlackRockaccumulating$204M2024.062024-08-13↑
BlackRockaccumulating$70M2024.062024-08-13↑
BlackRockaccumulating$1.4B2024.062024-08-13↑
BlackRockaccumulating$149M2024.062024-08-13↑
BlackRockaccumulating$35M2024.062024-08-13↑
BlackRockreducing$955K2024.062024-08-13↓
BlackRockaccumulating$1.1B2024.062024-08-13↑
BlackRockreducing$2M2024.062024-08-13↓
BlackRockreducing$272K2024.062024-08-13↓
BlackRockreducing$7M2024.062024-08-13↓
BlackRockaccumulating$38M2024.062024-08-13↑
BlackRockreducing$3M2024.062024-08-13↓
BlackRockreducing$2M2024.062024-08-13↓
BlackRockreducing$181K2024.062024-08-13↓
BlackRockreducing$22M2024.062024-08-13↓
Vanguard Groupaccumulating$1.9B2025.122026-01-29↑
Vanguard Groupreducing$1K2025.122026-01-29↓
Vanguard Groupaccumulating$408M2025.122026-01-29↑
Vanguard Groupaccumulating$1.4B2025.122026-01-29↑
Vanguard Groupreducing$6M2025.122026-01-29↓
Vanguard Groupaccumulating$5.0B2025.122026-01-29↑
Vanguard Groupaccumulating$79.5B2025.122026-01-29↑
State Streetaccumulating$38.0B2025.122026-02-13↑
Wellington Managementaccumulating$13.2B2025.122026-02-17↑
Wellington Managementaccumulating$226M2025.122026-02-17↑
Wellington Managementreducing$90M2025.122026-02-17↓
Wellington Managementreducing$59M2025.122026-02-17↓
Wellington Managementreducing$62M2025.122026-02-17↓
Wellington Managementreducing$75M2025.122026-02-17↓
Wellington Managementaccumulating$428M2025.122026-02-17↑
Wellington Managementreducing$11M2025.122026-02-17↓
Wellington Managementreducing$198M2025.122026-02-17↓
FMR (Fidelity)accumulating$19.5B2025.122026-02-17↑
FMR (Fidelity)accumulating$4.0B2025.122026-02-17↑
FMR (Fidelity)accumulating$2.3B2025.122026-02-17↑
FMR (Fidelity)accumulating$293M2025.122026-02-17↑
FMR (Fidelity)accumulating$1.5B2025.122026-02-17↑
FMR (Fidelity)accumulating$40M2025.122026-02-17↑

Kepemilikan institusional

Basis 13F · Q4 2025
InstitusiPerubahan% kepemilikanKuartal sblmSahamNilaiSEC
VanguardDipertahankan2.90%—290.0M saham$28,000M13F
Capital ResearchDitingkatkan0.50%—50.0M saham$4,800M13F
T. Rowe PriceDitingkatkan0.33%—33.0M saham$3,200M13F
WellingtonDitingkatkan0.22%—22.0M saham$2,100M13F
Total kepemilikan terlacak: 3.95%Total nilai: $38,100MBerdasarkan SEC EDGAR 13F-HR · keterlambatan 45 hari

Berita terkini

Memuat berita...

Analisis AI

Klik "Dapatkan Analisis AI" untuk analisis rantai pasok Eli Lilly and Company.

Info Perusahaan

Kantor Pusat

Indianapolis, Indiana, USA

Didirikan

1876

Karyawan

43,000+

Situs Web

lilly.com

Skor Kesenjangan Berita

Skor Kesenjangan20
Kesenjangan RendahKesenjangan Tinggi

Aktivitas Institusional

88

Skor Media

75

Posisi Kaskade

Peran dalam Kaskade

leader

Keterlambatan Tipikal

0 (trigger)

Eli Lilly's Mounjaro/Zepbound sales and clinical trial readouts set expectations for the entire GLP-1 obesity market.

Lihat Kaskade Lengkap

Gambaran umum sektor — 제약 / 바이오

Berita sektor

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Tema utama

  • •Mounjaro/Wegovy — 비만·당뇨 넘어 심혈관·신장·NASH 적응증 확대
  • •Moderna mRNA-4157 암백신 — 흑색종 49% 재발 감소 (NEJM)
  • •REGN dupilumab 다적응증 확대 → 10조+ 매출 가시성

Katalis mendatang

  • ◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)
  • ◆MRNA 암백신 FDA BLA 제출 예정